The USPTO has issued patent US12582622B2, granting intellectual property rights to Jazz Pharmaceuticals Ireland Limited for a method of treating idiopathic hypersomnia using sodium oxybate. The patent, effective March 24, 2026, covers specific treatment methods and was filed on October 8, 2021, with 29 claims.

This patent grant signifies a new intellectual property asset for Jazz Pharmaceuticals, potentially impacting market exclusivity for their sodium oxybate treatments for idiopathic hypersomnia. While this is a patent grant and not a regulatory rule, it has significant implications for market dynamics and competitive landscape within the pharmaceutical sector for this specific indication. Compliance officers in the pharmaceutical sector should note this development for competitive intelligence and potential impact on future market access or licensing discussions.